Lantheus Holdings, Inc. $LNTH Shares Sold by Carmignac Gestion

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Carmignac Gestion reduced its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 18.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 190,500 shares of the medical equipment provider's stock after selling 42,200 shares during the period. Carmignac Gestion owned 0.28% of Lantheus worth $18,593,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of LNTH. Janus Henderson Group PLC raised its stake in Lantheus by 72.7% during the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock worth $554,583,000 after purchasing an additional 2,610,118 shares during the period. Farallon Capital Management LLC grew its stake in shares of Lantheus by 79.9% during the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock valued at $475,590,000 after buying an additional 2,361,000 shares during the period. Westfield Capital Management Co. LP increased its holdings in shares of Lantheus by 2.2% during the 1st quarter. Westfield Capital Management Co. LP now owns 1,589,145 shares of the medical equipment provider's stock worth $155,101,000 after buying an additional 34,052 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in shares of Lantheus by 40.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock worth $135,025,000 after buying an additional 435,445 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Lantheus by 2.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,378,536 shares of the medical equipment provider's stock worth $134,534,000 after buying an additional 31,454 shares during the period. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Lantheus

In other news, insider Rajiv A. Patel sold 3,365,000 shares of the firm's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the sale, the insider directly owned 3,477,227 shares in the company, valued at $195,246,296.05. This trade represents a 49.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mary Anne Heino sold 26,066 shares of the business's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the transaction, the director owned 318,650 shares in the company, valued at approximately $24,481,879.50. This trade represents a 7.56% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 6,838,066 shares of company stock valued at $384,430,031. Corporate insiders own 2.00% of the company's stock.

Lantheus Stock Down 1.6%

Lantheus stock traded down $0.95 during midday trading on Friday, hitting $58.21. 2,306,660 shares of the company were exchanged, compared to its average volume of 2,558,465. The company has a market cap of $3.96 billion, a PE ratio of 15.48 and a beta of 0.14. Lantheus Holdings, Inc. has a fifty-two week low of $47.25 and a fifty-two week high of $118.21. The company's fifty day moving average price is $71.48 and its 200-day moving average price is $84.19. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.29 and a quick ratio of 4.07.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.08). Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The firm had revenue of $378.05 million during the quarter, compared to analyst estimates of $389.69 million. During the same period last year, the business earned $1.80 EPS. The firm's revenue was down 4.1% compared to the same quarter last year. On average, research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Truist Financial set a $63.00 price target on Lantheus and gave the company a "hold" rating in a research report on Monday, August 11th. JMP Securities decreased their target price on Lantheus from $112.00 to $73.00 and set a "market outperform" rating for the company in a report on Thursday, August 7th. Mizuho dropped their target price on shares of Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a research report on Thursday, August 7th. B. Riley reduced their price target on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research report on Monday, June 23rd. Finally, Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $105.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.